Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals Inc. has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for its investigational d...

Ionis Pharmaceuticals Inc. shares have declined by 1.4% during market hours on Monday, following a notable drop of 2.4% in premarket trading. This...

Ionis Pharmaceuticals Inc's Director, Wender Joseph H, exercised an option to buy 16,000 shares at a price of 24.42 on November 18, 2025. This tran...

Ionis Pharmaceuticals Inc. has seen significant insider trading activity, with Director Herman Joan E exercising an option to purchase 44,000 share...

Ionis Pharmaceuticals Inc (IONS) has experienced a decline in its stock price today. Social media discussions have highlighted notable updates rega...

On social media, discussions emerged regarding the recent FDA approval of Arrowhead Pharmaceuticals' drug Redemplo for familial chylomicronemia syn...

Ionis Pharmaceuticals Inc. is experiencing a positive price movement, having increased since Friday. The company's drug SPINRAZA, which treats spin...

Ionis Pharmaceuticals Inc. has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use rega...

Ionis Pharmaceuticals Inc. has priced $700 million in convertible senior notes due 2030 in a private placement to qualified institutional buyers, w...

Ionis Pharmaceuticals Inc. has announced a proposed offering of $700 million in convertible senior notes due 2030, aimed at refinancing its existin...

Ionis Pharmaceuticals Inc is experiencing a notable price increase, moving in tandem with the Biotechnology sector, which is also significantly hig...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) has reported positive outcomes from the pivotal Phase 3 CORE and CORE2 studies of olezarsen, which targe...

Ionis Pharmaceuticals Inc is currently trading lower, mirroring the broader market's decline. The stock is experiencing unusually high trading volu...

Ionis Pharmaceuticals Inc. has experienced significant insider stock transactions recently. Richard S. Geary, the Executive Vice President and Chie...